Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant
Stopped Lack of Enrollment
Conditions
- Acute Myeloid Leukemia and Myelodysplastic Syndrome
Interventions
- DRUG: Nivolumab
- DRUG: Ipilimumab
Sponsor
Hackensack Meridian Health
Collaborators